Approved · Notification · Phase 1 · filed 18 May 2026
Eli Lilly and Company proposes to acquire 100% of the shares in Kelonia Therapeutics, Inc. This share acquisition involves a US-based pharmaceutical company acquiring a clinical-stage biotechnology company focused on developing genetic medicines, including CAR-T therapies for oncology indications like multiple myeloma.
Eli Lilly and Company ( Eli Lilly ) proposes to acquire 100% of the issued shares in Kelonia Therapeutics, Inc ( Kelonia Therapeutics ) (the Acquisition ). Eli Lilly is a US-based pharmaceutical company, which discovers, develops, manufactures and markets human pharmaceutical products for various therapeutic areas, including diabetes, oncology, immunology and neuroscience. Eli Lilly is headquartered in Indianapolis, US and is publicly listed on the New York Stock Exchange. Eli Lilly has an Australian subsidiary that registers and markets medicine in Australia. Kelonia Therapeutics is a US-based clinical-stage biotechnology company focused on the development of genetic medicines using its in vivo gene placement system (iGPS). Kelonia Therapeutics is developing a pipeline of lentiviral-based in vivo CAR-T therapies primarily for oncology indications. Its lead asset (KLN-1010) is a clinical-stage (Phase 1) that uses iGPS to deliver an anti-BCMA CAR to T cells for treatment of multiple myeloma.